A spectacular effect of tocilizumab in Takayasu arteritis

Background: Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis. Case description: We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatma Saïd, Ines Naceur, Tayssir Ben Achour, Mayssam Jridi, Monia Smiti
Format: Article
Language:English
Published: SMC MEDIA SRL 2024-11-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/4868
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis. Case description: We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, the patient presented twice with clinical and radiological signs of activity, requiring an increase of corticosteroid dose and an increase in the methotrexate dose to 20 mg/week. Anti-IL-6R infusions were indicated. At the end of the fifth infusion, the patient was totally asymptomatic: she no longer experienced episodes of syncope or amnesia. Conclusion: Our case perfectly illustrates the effectiveness of anti-IL-6R in the treatment of Takayasu arteritis, especially in its refractory form.
ISSN:2284-2594